RECORDS ARE PUBLISHED REGULATORY ACTIONS. FIELDS THE ISSUING AUTHORITY DID NOT PUBLISH ARE MARKED AS NOT STATED, NEVER FILLED IN.
Drug Eye AfricaNational Actions, Continental Reach
Register / Egypt / DEA-EG-2024-0003
Egyptian Drug Authority · Egypt
DEA-EG-2024-0003
Tier 1 · Regulator-publishedUnclassifiedPublic warningStatus · active
Issuing authority
Egyptian Drug Authority (EDA)
Authority reference
periodic report no (3) For 2024
Date issued
Jan 2024
Recorded by us
2026-09-06 19:45:29 UTC
Product
Suprax 100mg/5ml (60 ml)
INN / active substance
Not stated by the issuing authority
Dosage form
Not stated by the issuing authority
Strength
Not stated by the issuing authority
Manufacturer
Not stated by the issuing authority
Manufacturer country
Not stated by the issuing authority
MAH or importer
Not stated by the issuing authority
Batch numbers
Not published with the notice
Expiry dates
Not published with the notice
Action type
Public warning
Classification
Not stated by the issuing authority
Indicative severity
Not assessed by Drug Eye Africa
Defect category
Not stated by the issuing authority
Product type
Not stated by the issuing authority
ATC code
Not stated by the issuing authority
Affected markets
Egypt — no market beyond the issuing country was named on the notice
Cross-border event
Not linked to a cross-border event
Notice text
Suprax 100mg/5ml (60 ml) Hikma Pharmaceutical industries 2722 طبقا لإفادة الشركة حول وجود عبوات مقلدةمن الصنف المذكور وقف تداول و ضبط وتحريز المستحضر المقلد عدم شراء المستحضرات الصيدلية الا من الصيدليات المرخصة. في حالة الشك في المستحضر الصيدلى يتم الرجوع الى هيئة الدواء المصرية سواء بالإتصال بالخط الساخن 15301او الموقع الإلكترونى الخاص بالهيئة. يمكن الضغط على الرابطللإطلاع علىالصور الخاصة بالمستحضر المقلد. يناير 2024 منشور غش تجاري اسم المستحضر الشركة المنتجة رقم التشغيلة سبب التحذير الإجراءات التصحيحية نصائح للمستهلكين
Original language: ar
Notice text in English
Notice. Counterfeit packs of Suprax 100mg/5ml (60 ml), of Hikma Pharmaceutical Industries, batch 2722, have been reported by the company. Circulation of the counterfeit product is to stop and the product is to be impounded and seized. Pharmaceutical products should be bought only from licensed pharmacies. Anyone in doubt about a pharmaceutical product should contact the Egyptian Drug Authority, by its hotline 15301 or through its website.
Machine translation, produced by Drug Eye Africa and not checked by the issuing authority. The authority stated only the text above it.
Status
Active
Superseded by
Not superseded. This is the current version.
Version
1

Provenance

Verification tier 1

Where this record came from, and what is held to show it.

Copy of the source
Taken and held by Drug Eye Africa, so the record survives the link above being moved or withdrawn. Not yet published at an address you can open.
Ask us for it and check it against the fingerprint below.
Fingerprint
ee735ef7e3ae12f1855ed027779c6a410902d0db8a56a6d924541abc670d2f33
SHA-256 of the copy held. Any file that produces this number is that copy, byte for byte; any file that does not is a different document.
Copy taken
2026-09-06 20:39:44 UTC
Cite this record
Drug Eye Africa (2024). DEA-EG-2024-0003: Suprax 100mg/5ml (60 ml) — Public warning, Egyptian Drug Authority. Register of African Regulatory Actions. https://drugeyeafrica.org/register/notice/eg/2024/dea-eg-2024-0003

Version history

No version history recorded for this record.
Corrections appear here and in the site-wide log. Records are superseded, never deleted.

Verification

Tier 1Published by the issuing regulator on its own channel and captured by Drug Eye Africa, with the source document archived.

Indexing

This record is indexable: it is dated, names a product, and carries either a batch number or a stated reason.

DEA-EG-2024-0003 — Suprax 100mg/5ml (60 ml) · Drug Eye Africa